Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr CriPec docetaxel PET biodistribution study in solid tumors
NL-OMON50409Phase 1Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of docetaxel in Nonhematologic neoplasms, sponsored by Vrije University Medical Center. Primary endpoints: Detection of tumor uptake of 89Zr CriPec docetaxel and Quantification of tumor uptake of 89Zr CriPec docetaxel. Started Apr 2018; status: active, not recruiting.
02
Drugs
docetaxel
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON50409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50409.